Xu MJ, Wei X, Lu Y, Sun L, Xie Y, Li MH. Severe hyperlipidemia associated with drug-induced cholestatic liver disease: A case report. World J Hepatol 2025; 17(12): 111414 [DOI: 10.4254/wjh.v17.i12.111414]
Corresponding Author of This Article
Ming-Hui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wuhm2000@sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Dec 27, 2025 (publication date) through Dec 29, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Xu MJ, Wei X, Lu Y, Sun L, Xie Y, Li MH. Severe hyperlipidemia associated with drug-induced cholestatic liver disease: A case report. World J Hepatol 2025; 17(12): 111414 [DOI: 10.4254/wjh.v17.i12.111414]
World J Hepatol. Dec 27, 2025; 17(12): 111414 Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.111414
Severe hyperlipidemia associated with drug-induced cholestatic liver disease: A case report
Meng-Jiao Xu, Xin Wei, Yao Lu, Lei Sun, Yao Xie, Ming-Hui Li
Meng-Jiao Xu, Xin Wei, Yao Lu, Yao Xie, Ming-Hui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, Beijing 100015, China
Lei Sun, Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, Beijing 100015, China
Ming-Hui Li, Infection, Clinical Cure and Immunology Joint Laboratory for Clinical Medicine, Capital Medical University, Beijing 100015, China
Co-first authors: Meng-Jiao Xu and Xin Wei.
Author contributions: Xu MJ and Wei X wrote the main manuscript text and prepared Figures 1 and 2, and they contributed equally to this manuscript as co-first authors; Lu Y, Xie Y, and Li MH approved the submitted version after modification; Sun L prepared Figure 3; Xie Y and Li MH edited the manuscript. All authors made a significant contribution to the work reported. All authors have read and approved the final manuscript.
Supported by Beijing Municipal Health Commission High-Level Public Health Technical Personnel Construction Project, No. discipline leader-03-26; Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support, No. ZLRK202301; Beijing Hospitals Authority “Peak” Talent Training Program, No. DFL20241803; and The National Key Research and Development Program, No. 2023YFC2306901 and No. 2023YFC2308105.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Hui Li, Department of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Peking University Ditan Teaching Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. wuhm2000@sina.com
Received: July 3, 2025 Revised: August 11, 2025 Accepted: November 21, 2025 Published online: December 27, 2025 Processing time: 180 Days and 19.5 Hours
Abstract
BACKGROUND
The global incidence of hyperlipidemia has been increasing on an annual basis, concomitant with improvements in living standards and dietary changes. Hyperlipidemia is closely associated with the development of numerous diseases, and in clinical cases, drug-induced cholestasis may lead to elevated serum cholesterol and triglyceride levels, a phenomenon known as secondary hyperlipidemia. Hyperlipidemia is recognized as a significant risk factor for the development of cardiovascular disease. Therefore, effective monitoring and control of lipid levels is crucial in the management of patients diagnosed with drug-induced cholestatic liver disease.
CASE SUMMARY
We present a special case of refractory hyperlipidemia associated with cholestatic liver disease in a 49-year-old woman.
CONCLUSION
In the treatment of clinical cases of drug-induced cholestatic liver disease and hyperlipidemia, it is essential for medical professionals to consider the patient’s overall condition, formulate an individualized treatment plan, and closely monitor the patient’s biochemical indices and clinical symptoms to ensure treatment efficacy and prognosis.
Core Tip: Hyperlipidemia is closely associated with the development of multiple diseases and is widely recognized as a major risk factor for cardiovascular disease. In clinical settings, drug-induced cholestatic liver disease can increase blood cholesterol and triglyceride levels, a condition known as secondary hyperlipidemia. Furthermore, lipid overload can exacerbate hepatic oxidative stress. Therefore, accurate recognition and management of hyperlipidemia are crucial for systemic health and the functioning of multiple organs.
